Navigation Links
Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
Date:5/15/2008

- Unprecedented amount of research reflects depth and breadth of collaboration with investigators worldwide to develop new treatments for

diverse forms of cancer

- Plenary session to highlight impact of Zometa(R), the leading IV bisphosphonate, on relapse rate of patients with early-stage breast cancer - Four oral sessions to feature RAD001, first oral once-daily continuous inhibitor of mTOR, including first results of RECORD-1 study in renal cell

carcinoma

- Updated Phase II results with Tasigna(R) in Philadelphia

chromosome-positive chronic myeloid leukemia to be presented

EAST HANOVER, N.J., May 15 /PRNewswire/ -- Novartis Oncology announced today that the 44th annual meeting of the American Society of Clinical Oncology (ASCO) will include an unprecedented amount of research drawing from Novartis Oncology's robust pipeline of investigational compounds and existing cancer therapies. Novartis Oncology's cancer therapies will be the subject of more than 170 abstracts at the meeting, and will be highlighted in a plenary session, as well as seven oral presentations.

A plenary session will feature the first efficacy results from the ABCSG-12 study, looking at the impact of Zometa(R) (zoledronic acid) on disease-free survival in patients with early-stage breast cancer (Abstract #LBA4: Sunday, June 1, 2008; 1:45 PM to 2:00 PM CDT). In addition, late-breaking data on the role of RAD001 (everolimus) as a potential new treatment option for patients with advanced kidney cancer who have failed standard therapies will be presented in an oral session (Abstract #LBA5026: Saturday, May 31, 2008; 4:30 PM-4:45 PM CDT).

"This is a particularly exciting year for Novartis Oncology in advancing research and touching the lives of thousands of cancer patients," said David Epstein, CEO & President of Novartis Oncology. "Our scientific presence at ASCO shows that N
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
2. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
3. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
4. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
5. Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation
6. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
9. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014   Bluegrass Vascular ... on innovating lifesaving devices and methods for vascular ... in Series A financing, which was led by ... the deal will allow Bluegrass Vascular to obtain ... System, enhance manufacturing capabilities, and proceed with US ...
(Date:7/30/2014)... SUNNYVALE, California , July 30, 2014 /PRNewswire/ ... GPU technology and CUDA programming expertise to big ... other markets  eInfochips, a leading engineering ... to clients to develop NVIDIA GPU-powered solutions for ... , high-performance computing (HPC), industrial ...
(Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- The global microbial identification ... methods, applications, end users, and geographies. Genotypic technology ... microbial identification market. This favorable growth is attributed ... and the time required for microbial identification along ... Furthermore, genotypic methods have high applications in clinical ...
Breaking Medicine Technology:Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6
... Nov. 10, 2011 Throughout the healthcare industry, compliance ... relations (PTR) groups are tightening as increased regulations intensify ... the pace of activity cycles are slowing and more ... Nearly 90% of pharma PTR groups feel ...
... HONOLULU, Nov. 10, 2011 Eli Lilly and Company ... Executive Officer John C. Lechleiter, Ph.D., today said new ... bring innovation to patients are needed to assure improved ... Lechleiter,s comments come as the United States hosts ...
Cached Medicine Technology:Restrictive Compliance Environment Weakens Professional and Trade Relations Group Impact 2Lilly CEO Lechleiter Outlines Opportunities for Improved Health and Economic Growth in Asia-Pacific Region 2Lilly CEO Lechleiter Outlines Opportunities for Improved Health and Economic Growth in Asia-Pacific Region 3Lilly CEO Lechleiter Outlines Opportunities for Improved Health and Economic Growth in Asia-Pacific Region 4
(Date:7/30/2014)... July 30, 2014 The family of ... has filed a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) ... Bernstein Liebhard LLP reports. According to the complaint, which ... of Vermont on July 25th, the decedent had been ... an irreversible brain bleed that ultimately led to his ...
(Date:7/30/2014)... 30, 2014 Visitors to our region ... $8,500 to ensure its protection. Bob Kiesendahl, one of ... to the Delaware Highlands Conservancy for donations collected through ... $2-per-stay donations add up fast, as visitors welcome the ... Delaware River Region. , The Kiesendahl family has owned ...
(Date:7/30/2014)... July 30, 2014 (HealthDay News) -- Some obese people ... the reward centers in their brains when they see ... how this mutation triggers feelings of pleasure and gratification ... help improve strategies designed to prevent overeating, the scientists ... obese. Obesity is typically caused by a combination ...
(Date:7/30/2014)... 2014 DRE Medical — a leading ... launch of its Medical Trade Shows & Conventions ... professionals and equipment vendors. , The calendar is a ... the United States and around the world. Hundreds of ... number is always growing. , Information listed on each ...
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people ... published this week in the peer-reviewed journal Quality of Life Research , a UCLA team led by Dr. Brennan Spiegel interviewed ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Gene Mutation May Make Food More Tempting 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3
... higher odds of heart attack, death, study found , , MONDAY, ... younger heart attack patients more prone to another heart attack, ... drug Plavix, researchers report. , The study is published in ... , Plavix plus low-dose aspirin are often used to prevent ...
... Experimental approach seemed to protect the animals from smoke,s ... News) -- In experiments in mice, scientists have shown ... the respiratory damage caused by cigarettes. , The finding ... disease (COPD) -- a chronic progressive lung disease involving ...
... Highway Traffic Safety Administration (NHTSA) revealed that an estimated ... will be on the roads this holiday season. In ... that involved a drunk driver from Thanksgiving through New ... the University of Georgia found that the most important ...
... Department of Energy,s (DOE) Brookhaven National Laboratory have determined ... neurotoxin a deadly toxin produced by certain bacteria ... in cosmetic and therapeutic applications such as reducing wrinkles ... online December 22, 2008, by the Journal of ...
... The Women,s Heart Health Initiative at the Cardiovascular Research ... fellowship dedicated to gender-specific research that will improve the ... The announcement will take place during a February luncheon ... unique challenges to successful diagnosis and treatment of heart ...
... Medicine (BUSM) have determined the optimal dose-management strategy to ... outcomes. Results of the study appear online in the ... and Haemostasis . , Warfarin is highly effective ... conditions. Numerous studies have focused on the underutilization ...
Cached Medicine News:Health News:Gene Ups Risk for Those on Blood-Thinner Plavix 2Health News:Gene Ups Risk for Those on Blood-Thinner Plavix 3Health News:Drug Shields Mice From Emphysema 2Health News:MU professor recommends changing drivers' perceptions of law enforcement to deter drunk driving 2Health News:Scientists reveal structure of new botulism nerve toxin subtype 2Health News:Scientists reveal structure of new botulism nerve toxin subtype 3Health News:Study shows optimal dose management of warfarin improves anticoagulation control 2
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
Medicine Products: